THERAPEUTIC MANAGEMENT OF PATIENTS INFECTED WITH SARS-CoV-2 VIRUS - A REVIEW

Authors

  • Nicoleta Blebea Ovidius University of Constanta, Faculty of Pharmacy, Constanta
  • Gabriela Mitea Ovidius University of Constanta, Faculty of Pharmacy, Constanta

DOI:

https://doi.org/10.12955/pmp.v2.163

Keywords:

COVID-19, SARS-CoV-2, pandemic, treatment, vaccine

Abstract

INTRODUCTION: Due to the rapid outbreak of the pandemic that causes SARS-CoV-2 infection and the increased rate of morbidity and mortality as a result of this new infection, the treatments pursued in therapy must have an increased potential to inhibit the replication of this virus.

OBJECTIVES: The main objective of this article was to describe the most current drug therapies and their mechanisms of action used in the treatment of COVID-19. In this article, we have collected the latest information and multilingual international scientific discoveries about the treatment of COVID-19.

RESULTS: Several compounds can be used to treat COVID-19 in order to reduce the duration of the disease and the rate of infection, to reduce the viral load, to prevent tissue damage, to stimulate the maturation of many cells, including immune cells in the human body and to reduce its severe symptoms. The most effective treatments were based on the antiviral drugs, antimalarial drugs, anti-inflammatory drugs, analgesics drugs, glycopeptide antibiotics, anticoagulants, vitamin C and vitamin D. The simplest and most direct approach to controlling SARS-CoV-2 outbreaks is the use of passive antibodies transferred from plasma to convalescent patients. Recently, studies have been completed for several vaccines that are approved against SARS-CoV-2.

CONCLUSION: Scientists around the world are collaborating and innovating to make tests, treatments and vaccines available to the public that will save lives collectively and end this pandemic.

References

Bischoff-F., H. A., Shao, A., Dawson-Hughes, B., Hathcock, J., Giovannucci, E., & Willett, W. C. (2010). Benefit-risk assessment of vitamin D supplementation. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 21(7), 1121–1132. https://doi.org/10.1007/s00198-009-1119-

Breining, P., Frølund, A. L., Højen, J. F., Gunst, J. D., Staerke, N. B., Saedder, E., Cases-Thomas, M., Little, P., Nielsen, L. P., Søgaard, O. S., & Kjolby, M. (2021). Camostat mesylate against SARS-CoV-2 and COVID-19-Rationale, dosing and safety. Basic & clinical pharmacology & toxicology, 128(2), 204–212. https://doi.org/10.1111/bcpt.13533

Cao, Y., Wei, J., Zou, L., Jiang, T., Wang, G., Chen, L., Huang, L., Meng, F., Huang, L., Wang, N., Zhou, X., Luo, H., Mao, Z., Chen, X., Xie, J., Liu, J., Cheng, H., Zhao, J., Huang, G., Wang, W., … Zhou, J. (2020). Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial. The Journal of allergy and clinical immunology, 146(1), 137–146.e3. https://doi.org/10.1016/j.jaci.2020.05.019

Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., Ruan, L., Song, B., Cai, Y., Wei, M., Li, X., Xia, J., Chen, N., Xiang, J., Yu, T., Bai, T., Xie, X., Zhang, L., Li, C., Yuan, Y., … Wang, C. (2020). A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. The New England journal of medicine, 382(19), 1787–1799. https://doi.org/10.1056/NEJMoa2001282

Cascella, M., Rajnik, M., Cuomo, A., Dulebohn, S. C., & Di Napoli, R. (2021). Features, Evaluation, and Treatment of Coronavirus (COVID-19). In StatPearls. StatPearls Publishing.

Charoenngam, N., Shirvani, A., Kalajian, T. A., Song, A., & Holick, M. F. (2020). The Effect of Various Doses of Oral Vitamin D3 Supplementation on Gut Microbiota in Healthy Adults: A Randomized, Double-blinded, Dose-response Study. Anticancer research, 40(1), 551–556. https://doi.org/10.21873/anticanres.13984

Colunga B., R., Berrill, M., & Marik, P. E. (2020). The antiviral properties of vitamin C. Expert review of anti-infective therapy, 18(2), 99–101. https://doi.org/10.1080/14787210.2020.1706483

Creech, C. B., Walker, S. C., & Samuels, R. J. (2021). SARS-CoV-2 Vaccines. JAMA, 325(13), 1318–1320. https://doi.org/10.1001/jama.2021.3199

Demsie, D. G., Gebre, A. K., Yimer, E. M., Alema, N. M., Araya, E. M., Bantie, A. T., Allene, M. D., Gebremedhin, H., Yehualaw, A., Tafere, C., Tadese, H. T., Amare, B., Weldekidan, E., & Gebrie, D. (2020). Glycopeptides as Potential Interventions for COVID-19. Biologics : targets & therapy, 14, 107–114. https://doi.org/10.2147/BTT.S262705

Flanagan, K. L., Best, E., Crawford, N. W., Giles, M., Koirala, A., Macartney, K., Russell, F., Teh, B. W., & Wen, S. C. (2020). Progress and Pitfalls in the Quest for Effective SARS-CoV-2 (COVID-19) Vaccines. Frontiers in immunology, 11, 579250. https://doi.org/10.3389/fimmu.2020.579250

Fragoulis, G. E., McInnes, I. B., & Siebert, S. (2019). JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis. Rheumatology (Oxford, England), 58(Suppl 1), i43–i54. https://doi.org/10.1093/rheumatology/key276

Gao, J., Tian, Z., & Yang, X. (2020). Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Bioscience trends, 14(1), 72–73. https://doi.org/10.5582/bst.2020.01047

Gautret, P., Lagier, J. C., Parola, P., Hoang, V. T., Meddeb, L., Mailhe, M., Doudier, B., Courjon, J., Giordanengo, V., Vieira, V. E., Tissot Dupont, H., Honoré, S., Colson, P., Chabrière, E., La Scola, B., Rolain, J. M., Brouqui, P., & Raoult, D. (2020). Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International journal of antimicrobial agents, 56(1), 105949. https://doi.org/10.1016/j.ijantimicag.2020.105949

Ghanbari, R., Teimoori, A., Sadeghi, A., Mohamadkhani, A., Rezasoltani, S., Asadi, E., Jouyban, A., & Sumner, S. C. J. (2020). Existing antiviral options against SARS-CoV-2 replication in COVID-19 patients. Future Microbiology, 15(18). https://doi.org/10.2217/fmb-2020-0120

Grant, W. B., Lahore, H., McDonnell, S. L., Baggerly, C. A., French, C. B., Aliano, J. L., & Bhattoa, H. P. (2020). Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths. Nutrients, 12(4), 988. https://doi.org/10.3390/nu12040988

Holshue, M. L., DeBolt, C., Lindquist, S., Lofy, K. H., Wiesman, J., Bruce, H., Spitters, C., Ericson, K., Wilkerson, S., Tural, A., Diaz, G., Cohn, A., Fox, L., Patel, A., Gerber, S. I., Kim, L., Tong, S., Lu, X., Lindstrom, S., Pallansch, M. A., … Washington State 2019-nCoV Case Investigation Team (2020). First Case of 2019 Novel Coronavirus in the United States. The New England journal of medicine, 382(10), 929–936. https://doi.org/10.1056/NEJMoa2001191

Huang, D., Yu, H., Wang, T., Yang, H., Yao, R., & Liang, Z. (2021). Efficacy and safety of umifenovir for coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. Journal of medical virology, 93(1), 481–490. https://doi.org/10.1002/jmv.26256

Ivashchenko, A. A., Dmitriev, K. A., Vostokova, N. V., Azarova, V. N., Blinow, A. A., Egorova, A. N., Gordeev, I. G., Ilin, A. P., Karapetian, R. N., Kravchenko, D. V., Lomakin, N. V., Merkulova, E. A., Papazova, N. A., Pavlikova, E. P., Savchuk, N. P., Simakina, E. N., Sitdekov, T. A., Smolyarchuk, E. A., Tikhomolova, E. G., Yakubova, E. V., … Ivachtchenko, A. V. (2020). AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, ciaa1176. Advance online publication. https://doi.org/10.1093/cid/ciaa1176

Kalil, A. C., Patterson, T. F., Mehta, A. K., Tomashek, K. M., Wolfe, C. R., Ghazaryan, V., Marconi, V. C., Ruiz-Palacios, G. M., Hsieh, L., Kline, S., Tapson, V., Iovine, N. M., Jain, M. K., Sweeney, D. A., El Sahly, H. M., Branche, A. R., Regalado Pineda, J., Lye, D. C., Sandkovsky, U., Luetkemeyer, A. F., … ACTT-2 Study Group Members (2021). Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. The New England journal of medicine, 384(9), 795–807. https://doi.org/10.1056/NEJMoa2031994

Keske, Ş., Tekin, S., Sait, B., İrkören, P., Kapmaz, M., Çimen, C., Uğur, S., Çelebi, İ., Bakır, V. O., Palaoğlu, E., Şentürk, E., Çağlayan, B., Çakar, N., Tabak, L., & Ergönül, Ö. (2020). Appropriate use of tocilizumab in COVID-19 infection. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 99, 338–343. https://doi.org/10.1016/j.ijid.2020.07.036

Klok, F. A., Kruip, M., van der Meer, N., Arbous, M. S., Gommers, D., Kant, K. M., Kaptein, F., van Paassen, J., Stals, M., Huisman, M. V., & Endeman, H. (2020). Incidence of thrombotic complications in critically ill ICU patients with COVID-Thrombosis research, 191, 145–147. https://doi.org/10.1016/j.thromres.2020.04.013

Lei, G. S., Zhang, C., Cheng, B. H., & Lee, C. H. (2017). Mechanisms of Action of Vitamin D as Supplemental Therapy for Pneumocystis Pneumonia. Antimicrobial agents and chemotherapy, 61(10), e01226-17. https://doi.org/10.1128/AAC.01226-17

Marineci C.D., Valeanu A., Negres S., Chirita C. (2021). Vaccination against COVID-19. Farmacist.ro, 198, 7-16. https://doi.org /10.26416/Farm.198.1.2021.4353

Martineau, A. R., Jolliffe, D. A., Hooper, R. L., Greenberg, L., Aloia, J. F., Bergman, P., Dubnov-Raz, G., Esposito, S., Ganmaa, D., Ginde, A. A., Goodall, E. C., Grant, C. C., Griffiths, C. J., Janssens, W., Laaksi, I., Manaseki-Holland, S., Mauger, D., Murdoch, D. R., Neale, R., Rees, J. R., … Camargo, C. A., Jr (2017). Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. BMJ (Clinical research ed.), 356, i6583. https://doi.org/10.1136/bmj.i6583

Mitea, G., Bucur, M., Dumitru, I. M., Rugina, S., & Bucur, L. (2020). Therapeutic options in SARS-CoV-2 infection. Farmacist.ro, 195, 14-19. https://doi.org/10.26416/Farm.195.4.2020.3729

Ravichandran, R., Purna, P., Vijayaragavan, S., Kalavakollu, R. T., Gaidhane, S., & Kumar, R. K. (2020). Efficacy and Safety of Indomethacin in Covid-19 patients. medRxiv

Richardson, P., Griffin, I., Tucker, C., Smith, D., Oechsle, O., Phelan, A., Rawling, M., Savory, E., & Stebbing, J. (2020). Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet (London, England), 395(10223), e30–e31. https://doi.org/10.1016/S0140-6736(20)30304-4

Rolain, J. M., Colson, P., & Raoult, D. (2007). Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century. International journal of antimicrobial agents, 30(4), 297–308. https://doi.org/10.1016/j.ijantimicag.2007.05.015

Stebbing, J., Phelan, A., Griffin, I., Tucker, C., Oechsle, O., Smith, D., & Richardson, P. (2020). COVID-19: combining antiviral and anti-inflammatory treatments. The Lancet. Infectious diseases, 20(4), 400–402. https://doi.org/10.1016/S1473-3099(20)30132-8

Vincent, M. J., Bergeron, E., Benjannet, S., Erickson, B. R., Rollin, P. E., Ksiazek, T. G., Seidah, N. G., & Nichol, S. T. (2005). Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virology journal, 2, 69. https://doi.org/10.1186/1743-422X-2-69

Yao, X., Ye, F., Zhang, M., Cui, C., Huang, B., Niu, P., Liu, X., Zhao, L., Dong, E., Song, C., Zhan, S., Lu, R., Li, H., Tan, W., & Liu, D. (2020). In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 71(15), 732–739. https://doi.org/10.1093/cid/ciaa237

Yethindra, V., Tagaev, T., Uulu, M., S., & Parihar, Y. (2020). Efficacy of umifenovir in the treatment of mild and moderate COVID-19 patients. International Journal of Research in Pharmaceutical Sciences, 11(SPL1), 506-509. https://doi.org/10.26452/ijrps.v11iSPL1.2839

Zhang, L., Yan, X., Fan, Q., Liu, H., Liu, X., Liu, Z., & Zhang, Z. (2020). D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. Journal of thrombosis and haemostasis : JTH, 18(6), 1324–1329. https://doi.org/10.1111/jth.14859

Downloads

Published

2021-10-24

How to Cite

Blebea, N. ., & Mitea, G. . (2021). THERAPEUTIC MANAGEMENT OF PATIENTS INFECTED WITH SARS-CoV-2 VIRUS - A REVIEW. Proceedings of CBU in Medicine and Pharmacy, 2, 9-16. https://doi.org/10.12955/pmp.v2.163